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Fibrillary glomerulonephritis (FGN) is a rare proliferative form of glomerular disease characterized by
randomly oriented ﬁbrillar deposits with a mean diameter of 20 nm. By immunoﬂuorescence (IF), the
deposits stain for IgG, C3, and k and l light chains, suggesting that the ﬁbrils may be composed of antigenantibody immune complexes. A recent major advance in our understanding of the pathogenesis of FGN
resulted from the discovery that a major component of the ﬁbrils is DNA-J heat-shock protein family
member B9 (DNAJB9), and immunohistochemical staining for DNAJB9 now makes it possible to diagnose
FGN in the absence of ultrastructural evaluation. FGN has a poor prognosis, treatment options are
currently limited, and transplant recurrence is not uncommon.
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GN is a rare form of glomerulonephritis that was
ﬁrst described in 19771 and is deﬁned by the ultrastructural ﬁnding of organized, randomly oriented,
nonbranching ﬁbrils with a mean diameter of 20 nm
(range 15–25 nm). The diagnosis of FGN can only be
established by renal biopsy, and the incidence of FGN
in native renal biopsies is less than 1%.2–5 The ﬁbrils
that characterize FGN are predominantly conﬁned to
glomeruli and stain intensely by IF for IgG, C3, k, and
l, strongly suggesting that the ﬁbrils are composed of
a complex of antibodies and antigens. The absence of
staining for Congo red (with rare exception) and the
composition of the ﬁbrils help to differentiate FGN
from amyloidosis, while the diameter of the ﬁbrils and
the absence of a microtubular appearance with a hollow core help differentiate FGN from immunotactoid
glomerulopathy.

F

Clinical Features
The 3 largest clinical series on FGN, which include a
total of 187 patients, are reviewed in Table 1.4–7 These
clinical series include the initial series from Columbia
University with 61 patients,4 a cohort from the Mayo
Clinic that initially included 66 patients5 but was later
expanded to include 84 patients,6 and a more recent
report of 42 patients from the University of North
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Carolina (UNC).7 The clinical data from each of the 3
series are provided in Table 1, along with weighted
averages of the 3 studies. The mean age of presentation
was the sixth decade in all 3 cohorts, and 66% of patients were female. White race was most frequent, albeit
less so in the UNC study, possibly related to demographics of the geographic region. At the time of
presentation, 70% of patients had renal insufﬁciency,
and the mean serum creatinine was 2.9 mg/dl. The mean
24-hour urine protein was 5.7 g/d, and 36% of patients
met criteria for full nephrotic syndrome (deﬁned by a 24hour urine protein >3 g/d, serum albumin <3.5 mg/dl,
and edema). Hematuria was documented in 82% of
subjects.
The disease associations with FGN were somewhat
more variable between the 3 studies. The prevalence
of concurrent HCV infection ranged from 7% to 27%
(mean, 13%); notably, all 7 of the patients with FGN
and hepatitis C virus infection in the UNC series were
African American. The prevalence of concurrent
dysproteinemia, deﬁned by the presence of a serum or
urine M-spike or positive immunoﬁxation, varied
from 4% to 42% (mean, 13%). The clinical data were
more consistent with respect to coexistent autoimmune disease, diabetes mellitus, and malignancy.
Among patients with FGN, autoimmune disease was
seen in 11% of patients, diabetes mellitus in 24%,
and malignancy in 9%. Examples of autoimmune
diseases seen in patients with FGN include Crohn’s
disease, lupus, Grave’s disease, and idiopathic
thrombocytopenic purpura. Given the incidence of
these conditions, we recommend screening for hepatitis C virus, dysproteinemia, autoimmune disease,
917
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Table 1. Clinical characteristics of patients with FGN in the 3 largest cohorts
Columbia (n [ 61)
Age, yr

57

White race, %

92

Female, %

61

Creatinine, mg/dl
Renal insufﬁciency, %
Proteinuria, g/d
Full nephrotic syndrome, %
Hematuria, %
Hepatitis C, %
Autoimmune disease, %
Diabetes mellitus
Malignancy, %
Dysproteinemia, %

Mayo Clinic (n [ 84)

3.1
69
6.4

59
NA
74
2.5
71
5.1

52

25

60

90

UNC (n [ 42)

Weighted average

54

57

71

83

60

66

3.2
NA
5.7
NA
97
27 (7/26 patients)

2.9
70
5.7
36
82

17 (6/34 patients)

7

5

14

13

11

20

24

28

24

7

10

12

15 (7/46 patients)

4

42 (8/19 patients)

13

9
13

FGN, Fibrillary glomerulonephritis; UNC, University of North Carolina.

diabetes mellitus, and malignancy in patients with
FGN.
Pathology
FGN is associated with 5 patterns of glomerular
involvement by light microscopy, which correlate with
clinical presentation and outcome4 (Figure 1). The most
common light microscopy appearance of FGN in the
series from Columbia University was a membranoproliferative pattern (MPGN) in which there is
mesangial proliferation and expansion, accompanied by
glomerular basement membrane (GBM) duplication and
cellular interposition that attenuate the capillary
lumen4 (Figure 1a and b). Glomerular capillary lumen
attenuation and obliteration also are seen in the diffuse
proliferative pattern of FGN, in which there is mesangial and endocapillary proliferation, often accompanied
by inﬁltrating mononuclear leukocytes and crescent
formation. In contrast, the mesangial proliferative
pattern of FGN, which is the most common pattern in
the majority of case series,3,5,6 is characterized by solely
mesangial proliferation and expansion in the absence of
involvement of the glomerular capillary lumen. In the
rare membranous pattern, there is GBM thickening
with spike formation, which, similar to the mesangial
proliferative pattern, is not accompanied by cellular
proliferation or GBM duplication that attenuate capillary lumina. Lastly, the diffuse sclerosing pattern of
FGN has been deﬁned by the presence of >70% global
glomerulosclerosis.4 The mesangial proliferative and
membranous patterns of FGN are associated with a
lower serum creatinine level and a lower incidence of
nephrotic syndrome at the time of presentation and the
best long-term prognosis. Not surprisingly, the diffuse
sclerosing pattern is associated with the worst prognosis, whereas the MPGN and diffuse proliferative
patterns are intermediate with respect to presenting
features and outcome. Notably, the most common
918

pattern in the Columbia series4 was MPGN (44% of
biopsies), whereas the most common ﬁnding in the
Mayo Clinic series5 was the mesangial proliferative
pattern, seen in 71% of patients, which may explain
the better outcomes reported in the latter study. Of
note, the ﬁbrillary deposits are associated with
mesangial and in some cases GBM expansion by weakly
eosinophilic material that appears pale with the periodic acid–Schiff stain and blue-gray with the trichrome
stain and are nonargyrophilic.
The IF ﬁndings in FGN include somewhat ill-deﬁned,
“smudged” deposits that stain most intensely for IgG
(Figure 1c), usually accompanied by C3, k, and l, and
sometimes also associated with staining for C1q, IgM,
and/or IgA. In approximately 5% of cases of FGN, the
deposits stain by IF for k or l, but not both.4,6,7 This
light chain restriction—a ﬁnding that suggests that the
ﬁbrillary deposits may have a monoclonal composition—
often correlates with the presence of dysproteinemia.
The deposits in FGN are nearly always present in a
mesangial distribution, whereas GBM staining is present
in most cases with the MPGN, diffuse proliferative, and
membranous patterns. IF staining for subtypes of IgG
most often reveals positivity for IgG1 and IgG4, in the
absence of IgG2 and IgG3,4 and the intensity of staining
for IgG4 typically exceeds that for IgG1.8 Of note, IF
reveals focal positivity in tubular basement membranes
in a signiﬁcant minority of cases of FGN.
Ultrastructural evaluation is critical to establishing the
diagnosis of FGN. Electron microscopy reveals nonbranching, randomly oriented ﬁbrils with a mean diameter of 20 nm (range, 15–25 nm), which are nearly always
present in the mesangial matrix and in most cases also
permeate the lamina densa of the GBM, with minimal
extension into the subendothelial or subepithelial regions
(Figure 1d and e). Extensive foot process effacement is
seen in areas of ﬁbril accumulation. Intermixed electrondense deposits of the usual, granular type are commonly
Kidney International Reports (2019) 4, 917–922
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Figure 1. Renal biopsy ﬁndings in ﬁbrillary glomerulonephritis (FGN). (a) A glomerulus exhibits global mesangial proliferation with expansion of
the mesangial matrix by amorphous eosinophil material that corresponds with the ﬁbrillary deposits and also involves and mildly expands the
peripheral capillary walls of the glomerular basement membrane (GBM). In addition to mesangial proliferation, there is evidence of endocapillary
proliferation with focal inﬁltrating mononuclear leukocytes (hematoxylin and eosin; original magniﬁcation 400). (b) The Jones methenamine
silver stain highlights the eosinophilic deposits that expand the mesangial matrix and GBMs, and also demonstrates segmental GBM
duplication with cellular interposition (“membranoproliferative features”; original magniﬁcation 400). (c) Immunoﬂuorescence staining for
IgG reveals intense global mesangial and glomerular capillary wall–ill-deﬁned, smudged positivity. Identical staining for C3, k, and l was
noted (original magniﬁcation 400). (d) Ultrastructural evaluation demonstrates abundant ﬁbrils that permeate and expand the GBM and also
are seen in the mesangial matrix. Overlying visceral epithelial cells exhibit complete foot process effacement (original magniﬁcation 12,000).
(e) At higher magniﬁcation, the ﬁbrils are randomly oriented with a mean diameter of 20 nm (original magniﬁcation 60,000).
(f) Immunohistochemical staining for DNA-J heat-shock protein family member B9 is strongly positive in the mesangial matrix and GBMs,
which is the same distribution as the randomly oriented ﬁbrils in this biopsy showing FGN (original magniﬁcation 400).

encountered in FGN but typically are relatively focal in
distribution. Of note, rare cases of cryoglobulinemic
glomerulonephritis form ﬁbrils with an ultrastructural
appearance that is identical to FGN; as such, testing for
circulating cryoglobulins is recommended before establishing a deﬁnitive diagnosis of FGN.
Pathogenesis
Until recently, understanding of the pathogenesis of FGN
was limited, in part because of the lack of an available
Kidney International Reports (2019) 4, 917–922

animal model for this condition. The observation that
cryoglobulinemic glomerulonephritis can appear identical at the ultrastructural level to FGN, as well as the
similar composition of the deposits by IF, raise the possibility of a similar pathogenesis. There is a single report
of a patient with FGN for whom serum was stored at 4  C
for 4 months and then recovered.9 The serum contained
a cryoprecipitate that did not dissolve upon rewarming,
suggesting that the ﬁbrils of FGN might represent an
irreversible “slow cryoglobulin.”9
919
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A major breakthrough in our understanding of FGN
occurred in 2018 when 2 independent groups, working
at the Mayo Clinic10 and the University of Washington,11 utilized laser capture microdissection to extract
glomeruli from biopsy specimens of patients with FGN
followed by liquid chromatography–assisted tandem
mass spectrometry. These groups simultaneously
identiﬁed DNAJB9 as one of the most abundant proteins in the FGN glomerular proteome, but it was not
present in glomeruli with amyloidosis, other forms of
glomerulonephritis, or normal controls. DNAJB9 was
shown to co-localize with IgG and components of the
classic complement pathway in glomeruli. These
studies suggest that DNAJB9 may act as an autoantigen
in FGN.
DNAJB9, also referred to as ERdj4 (or Mdg-1), is a
223-amino acid member of the DNAJ family of proteins that act as co-chaperones for the heat-shock
protein 70 family members including, most notably,
binding immunoglobulin protein.12–15 The heatshock protein 70 family members are thought to be
important chaperones in the endoplasmic reticulum
(ER), playing a role in protein folding, unfolding,
translocation, and degradation. DNAJB9 functions as
a co-chaperone to binding immunoglobulin protein,
assisting in protein folding and the degradation of
misfolded proteins, termed the “unfolded protein
response.” In particular, DNAJB9 may be important
in the recognition of misfolded proteins in order to
mark them for degradation14 and also may inhibit the
apoptotic effect of p53 on cells under conditions of
cell stress,15 leading to the suggestion that increased
expression of DNAJB9 may represent a marker of
increased ER stress.14–16 DNAJB9 is present at low
levels in the ER of most cell types. Nasr et al.6 identiﬁed expression of DNAJB9 by immunohistochemical
staining in the cytoplasm of neurons; gastrointestinal,
pulmonary, gynecologic, and breast epithelium; and
lymphocytes, to name a few. In the normal kidney,
DNAJB9 is present at low levels in renal tubular
epithelial cells, podocytes, and mesangial and endothelial cells. At present, the only disease known to be
associated with large amounts of extracellular deposition of DNAJB9 is FGN.
With respect to the role of DNAJB9 in the development of FGN, peptide analysis has demonstrated that
the DNAJB9 detected in FGN represents the full length,
223-amino acid protein, and genetic sequencing of 2
patients with FGN did not reveal pathogenic mutations.10 The absence of additional components of ER
stress pathways and unfolded protein response by mass
spectrometry argue against a central role of ER stress in
the pathogenesis of FGN.11 These observations, as well
as the co-localization of DNAJB9 with IgG and
920

components of the classic complement pathway, suggest an autoimmune pathogenesis with DNAJB9 acting
as the putative autoantigen. Many questions remain
unanswered, including how DNAJB9 forms ﬁbrils and
whether this happens before or after binding to IgG. If
FGN has an autoimmune pathogenesis, why haven’t
attempts to treat patients with immunosuppression
been more successful? Of note, if overexpression of
DNAJB9 plays a central role in the pathogenesis of
FGN, then potential alternative pathways for treatment
exist. DNAJB9 has been shown to be inducible by the
Ras/Raf/extracellular signal–regulated kinase pathway
in response to p53,16 and several kinase inhibitors
currently in use interfere with this pathway.17 Additional steps in our understanding of FGN will include
studies that examine circulating levels of DNAJB9 and
anti-DNAJB9 antibodies, and the potential development of an animal model.
Data on the sensitivity and speciﬁcity of DNAJB9
staining for the diagnosis of FGN are convincing. In
the largest study to date that includes renal biopsy
specimens from patients with FGN (84), amyloidosis
(21), other forms of glomerular disease (98), and
healthy normal control subjects (11), staining for
DNAJB9 was found to have a sensitivity of 98% and
speciﬁcity of 99% for the diagnosis of FGN6
(Figure 1f). Of note, the 2 cases of FGN that lacked
staining for DNAJB9 were atypical in that the IF
staining was positive for IgG but negative for both k
and l. The single non-FGN case with positive staining
for DNAJB9 exhibited ﬁndings most compatible with
smoking-associated nodular glomerulosclerosis and
exhibited only focal staining in 2 of 17 glomeruli, rather
than the diffuse staining typical of FGN. Thus the reported sensitivity of 98% and speciﬁcity of 99% may
represent an underestimate. Of note, all 9 biopsies with
immunotactoid glomerulopathy and 6 with cryoglobulinemic glomerulonephritis were negative, supporting the distinction between FGN and these entities.4
Importantly, the availability of immunohistochemical
staining for DNAJB9 as a marker of FGN allows for more
rapid diagnosis of this entity and, more importantly,
provides a method to establish the diagnosis of FGN in
the many areas of the world in which electron microscopy is not readily available.
A recent report from the Mayo Clinic illustrates how
the discovery of DNAJB9 in FGN can have practical
implications.18 The report described 18 patients with
renal biopsy ﬁndings compatible with FGN, but the
deposits exhibited apple-green birefringence when
stained with Congo red and viewed under polarized
light.18 This demonstration of “Congophilia” is a characteristic feature of amyloidosis that often is used to
exclude the diagnosis of FGN. Mass spectrometry and
Kidney International Reports (2019) 4, 917–922
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immunohistochemical staining revealed abundant
expression of DNAJB9 and the absence of a proteomic
signature of amyloidosis. As such, these cases were
appropriately labeled “Congophilic ﬁbrillary glomerulonephritis,” a diagnosis that previously could not have
been made and that could have led to the inaccurate
diagnosis of amyloidosis, with signiﬁcant treatment
implications.
Treatment and Prognosis
The prognosis for patients with FGN remains poor,
with limited data to suggest optimal therapy. In the
series from Columbia University, the median time to
end-stage renal disease (ESRD) was 24.4  15.2 months,
and predictors of outcome on multivariate analysis
included initial serum creatinine and degree of interstitial ﬁbrosis.4 In the initial series from the Mayo
Clinic, 44% of patients reached ESRD during a mean
follow-up period of 52.3 months, and the strongest
predictor of outcome on multivariate analysis was initial
serum creatinine, followed by age, 24-hour urine protein, and degree of glomerulosclerosis.5 On univariate
analysis in both studies, the pattern of glomerular
involvement seen by light microscopy affected clinical
outcomes, and the increased presence of a mesangial
pattern in the Mayo Clinic cohort likely played a role in
the better prognosis reported in that series. In the series
from UNC, the median time to ESRD was 13 months,
with poorer outcomes in African American patients.7
Immunosuppressive treatment was administered to
36% of patients in the series from Columbia University
and 48% of patients in the series from the Mayo Clinic
and UNC.4,5,7 The most common form of treatment was
steroids, with or without a second agent, including
most notably cyclophosphamide or rituximab. A
beneﬁt of immunosuppression could not be detected in
these small, retrospective studies in which patients
with more severe disease were more likely to have been
treated. In 2013, Javaugue et al.8 reported that 5 of 7
patients with FGN who were treated with rituximab
(2–4 injections of 375 mg/m2) attained a partial remission, deﬁned by a >50% decrease in 24-hour urine
protein accompanied by <15% decline in estimated
glomerular ﬁltration rate, compared with baseline. In
this series, only 1 of 3 patients treated with cyclophosphamide, 0 of 5 patients treated with steroid
monotherapy, and 0 of 4 patients treated with cyclosporine had a response. Of note, baseline estimated
glomerular ﬁltration rate was higher in responding
patients (76 vs. 42 ml/min).
In 2014, Hogan et al.19 published a report on the
largest series of patients with FGN who were treated
with rituximab. This series included 12 patients, the
majority of whom had an MPGN pattern revealed by
Kidney International Reports (2019) 4, 917–922
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light microscopy. The serum creatinine level at
baseline ranged from 0.7 to 3.0 mg/dl, with a serum
creatinine level >1.2 mg/dl noted in 9 of 12 patients.
The majority of patients had not received prior
immunosuppression, and most (11 of 12) received 2
doses of rituximab separated by 2 weeks. Four of the
12 patients (33%) had appeared to have a clinical
response, referred to as “nonprogression” and deﬁned
by stable renal function, over a follow-up period of 14
to 83 months (mean 40 months); 3 of the 4 patients
also had a signiﬁcant decline in proteinuria. However,
the remaining 8 patients experienced progressive
renal disease, including 5 who reached ESRD. Of note,
the “nonprogression” group included all 3 patients
with a baseline serum creatinine #1.2 mg/dl. In the
UNC series, only 1 of 9 patients treated with rituximab met criteria for “nonprogression.”7 Conclusions
regarding immunosuppressive therapy for FGN
cannot be drawn from these limited data, although
rituximab may offer beneﬁt in patients with FGN,
particularly in patients with relatively normal baseline renal function. Additional studies are needed to
address this issue.
Transplantation
Fourteen patients with ESRD secondary to FGN at the
Mayo Clinic underwent renal transplantation,
including 5 with preemptive transplants. At a mean
follow-up of 51 months, 5 patients (36%) had a biopsyproven recurrence of FGN, including 2 patients who
lost their allograft as a result of FGN recurrence.5 Two
patients in the Columbia series underwent renal
transplantation; neither had a clinical recurrence at 4
and 8 years of follow-up, although neither patient had
undergone a renal allograft biopsy.4 A recent report
from Australia and Zealand, using the ANZDATA registry, reported on the outcomes of 13 patients who had
ESRD resulting from FGN and received allografts.20
Only 1 of the 13 patients had a recurrence of FGN,
which ultimately led to allograft failure 4.6 years after
the recurrence was diagnosed. Outcomes for transplantation in FGN were similar to the overall transplant
population with respect to 10-year patient and renal
allograft survival.20 In summary, renal transplantation
is a viable option for patients with FGN, but the risk of
recurrence is not negligible.
In conclusion, FGN is a rare form of glomerular
disease characterized by distinctive randomly oriented, nonbranching ﬁbrils with a mean diameter of
20 nm (range 15–25 nm). Recent studies indicate that
the ﬁbrils contain IgG, complement components, and
DNAJB9, the latter of which now makes it possible to
diagnose FGN in the absence of electron microscopy.
The prognosis for FGN is poor, therapeutic options
921
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are limited, and optimal therapy remains to be
deﬁned.
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